Mainz Biomed N.V. has entered into a technology partnership with UK-based EDX Medical Group plc. Under this agreement, EDX Medical will gain access to Mainz Biomed’s molecular diagnostic technology.
This collaboration is part of EDX Medical’s strategy to expand its portfolio of products for sale in the UK. The partnership aims to improve access to high-quality cancer diagnostics in the region.
Guido Baechler, CEO of Mainz Biomed, stated that merging their expertise with EDX Medical’s capabilities will provide a reliable and meaningful contribution to early cancer detection and prevention in the UK.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.